|
|
 |
|
Viewing report
|
|
|
|
Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
GBI Research, April 2011, Pages: 105
Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
Summary
GBI Research's pharmaceutical research, “Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines”, provides insights into the global biotech M&A and licensing strategies. The report provides an in-depth analysis of the major M&A trends in the biotech industry along with the major drivers leading to an increased M&A activity in the current biotech industry. The report also delves into the M&A scenario in RNA therapeutics, monoclonal antibodies, biomarkers, biosimilars and global vaccines market. In addition, the report also analyzes the top 10 biotech companies with respect to the licensing agreement activities.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.
GBI Research analysis revealed that acquisitions, as an M&A strategy, dominate the biotech industry with a total of 72% of the M&A deals involving acquisitions. Acquisition strategy was adopted by biotech companies to have high speed access to resources, avoid barriers of entry and expand their portfolio of products and to improve their asset valuation. On the other hand, co-development deals dominates the licensing strategies landscape as compared to licensing agreements and are expected to increase at a higher rate in future. Co-development deals in the biotech industry witnessed a drastic increase in 2010 from 2009. There were 241 co-development activities that occurred in the year 2009 compared to 216 that occurred between January 2010 and August 2010. RNA therapeutics pipeline is the most promising with more than 89% of the licensing deals occurred for discovery and preclinical stage of development. The trend indicates that the future of RNA therapeutic research and development will be prosperous for at least the next five years.
Scope
The scope of this report includes -
- Major market trends that are expected to shape the licensing and deal making in biotech industry
- Key drivers that have a significant impact on licensing and deal making in biotech.
- Licensing and deal making market trends across five segments which include RNA therapeutics, monoclonal antibodies, biomarkers, biosimilars and global vaccines market.
- Licensing and deal making market segmentation by phase, type, geography and value
- Competitive benchmarking of leading biotech companies active in licensing and deal making
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop market-entry and market expansion strategies by identifying the leading areas for licensing and deal making in the biotech industry.
- Enable better product lifecycle management by identifying key phases of product licensing agreements.
- Develop segment specific strategies for licensing and deal making in biotech
- Develop key strategic initiatives by understanding the key licensing and deal making focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
|
|
|
|
